Originally Aired: December 3, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Recent successes using CAR-T therapies have allowed investigators to expand their research fforts to a wide array of treatment possibilities for patients. Commercialization of autologous CAR T-cells brings about a host of challenges that biomanufacturers must solve in order to dvance their production pipelines. As such, implementation of process control and automa- ion, as well as assurance of supply, are key to consistent, high-quality CAR T-cell production. The use of functionally closed systems with the ability to monitor and control processes hrough online sensors can enable process control. Combined with the use of consistent, erum-free T-cell optimized media as well as low E&L, single-use consumables, this process can enable manufacturers to be well on their way to creating high-quality, potent therapies. In this GEN webinar, we will learn more about online monitoring for process control during he successful expansion of CAR T-cells.

A live Q&A session followed the presentation, offering you a chance to pose questions to our expert panelist.

Julia Hupfeld, PhD
Julia Hupfeld, PhD
Scientist, Regenerative Medicine PD


Sartorius logo


This site uses Akismet to reduce spam. Learn how your comment data is processed.